logo Hematology/Oncology Research Studies: Open for Enrollment Date: 05/27/20


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Solid Tumors

NCT#/Phase: NCT03155620
Phase 2
IRB#: 2017-095d
Description: This is a subprotocol of the MATCH trial APEC1621 and is a phase 2 trial of LY3023414 in children with recurrent or refractory solid tumors, CNS tumors, and non-Hodgkin lymphomas harboring specified activating mutations of the PI3K/MTOR pathway. The study aims to determine the objective response rate of LY3023414, a potent orally bioavailable small molecule inhibitor of class 1 PI3K isoforms, MTOR, and DNAPK.
Inclusion: Individuals who are between 12 months and 21 years of age and given a therapy assignment to MATCH to APEC1621D.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group (COG)
Principal Investigator(s): Carla Golden, MD
Contact(s): Diane Olszewski (510-428-3885 x 3246)
COG CRA Office (510-428-3885 x8334)
Study Link: https://clinicaltrials.gov/ct2/show/NCT03155620

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000